Cuts and shake-up as GRObio reviews strategy

21 March 2025

US biotech GRO Biosciences is weighing the way forward for its lead gout program following a quiet restructuring that saw a reduction in research staff and key leadership changes.

The Cambridge, Massachusetts-based firm confirmed it had recently reorganized operations, leading to staff cuts focused on its research team. In a statement emailed to The Pharma Letter, the firm said it is now: “exploring strategic alternatives to advance its lead asset, ProGly-Uricase, a potential best-in-class treatment for refractory gout into the clinic.”

GROBio added it is assessing: “multiple options for the development and advancement of its platform and intellectual property,” but declined to comment further.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK